Clinical Trial Detail

NCT ID NCT04068181
Title Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Amgen
Indications

melanoma

Therapies

Pembrolizumab + Talimogene laherparepvec

Age Groups: adult senior

No variant requirements are available.